CCL2 and cancer: We have demonstrated that Oligo-Fucoidan reduces IL-6 and MCP-1/CCL2 expression and secretion in the ETO-treated cancer cells [13]; thus, Oligo-Fucoidan may control autocrine loops in cancer cells and paracrine pathways in the innate and/or adaptive immune systems.